317 related articles for article (PubMed ID: 35712797)
1. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.
Toussi SS; Neutel JM; Navarro J; Preston RA; Shi H; Kavetska O; LaBadie RR; Binks M; Chan PLS; Demers N; Corrigan B; Damle B
Clin Pharmacol Ther; 2022 Oct; 112(4):892-900. PubMed ID: 35712797
[TBL] [Abstract][Full Text] [Related]
2. Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19.
Singh RSP; LaBadie RR; Toussi SS; Shi H; Berg JK; Neutel JM; Aggarwal S
J Clin Pharmacol; 2024 Feb; 64(2):145-154. PubMed ID: 37751891
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
Yang H; Yu X; Hou W; Liu X; Chen J; Zhang Y; Wang Y; Zhu Y; Qian Q; Ma K; An Z
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0138423. PubMed ID: 38289075
[TBL] [Abstract][Full Text] [Related]
4. Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis.
Chan PLS; Singh RSP; Cox DS; Shi H; Damle B; Nicholas T
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1897-1910. PubMed ID: 37803876
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B
Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893
[TBL] [Abstract][Full Text] [Related]
6. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
[TBL] [Abstract][Full Text] [Related]
7. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
[TBL] [Abstract][Full Text] [Related]
8. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.
Park JJ; Kim H; Kim YK; Lee SS; Jung E; Lee JS; Lee J
J Korean Med Sci; 2023 Oct; 38(42):e347. PubMed ID: 37904658
[TBL] [Abstract][Full Text] [Related]
10. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
Hammond J; Fountaine RJ; Yunis C; Fleishaker D; Almas M; Bao W; Wisemandle W; Baniecki ML; Hendrick VM; Kalfov V; Simón-Campos JA; Pypstra R; Rusnak JM
N Engl J Med; 2024 Apr; 390(13):1186-1195. PubMed ID: 38598573
[TBL] [Abstract][Full Text] [Related]
11. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
12. Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants.
Cox DS; Rehman M; Khan T; Ginman K; Salageanu J; LaBadie RR; Wan K; Damle B
Br J Clin Pharmacol; 2023 Nov; 89(11):3352-3363. PubMed ID: 37354048
[TBL] [Abstract][Full Text] [Related]
13. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Singh RSP; Toussi SS; Hackman F; Chan PL; Rao R; Allen R; Van Eyck L; Pawlak S; Kadar EP; Clark F; Shi H; Anderson AS; Binks M; Menon S; Nucci G; Bergman A
Clin Pharmacol Ther; 2022 Jul; 112(1):101-111. PubMed ID: 35388471
[TBL] [Abstract][Full Text] [Related]
14. Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.
Wang Z; Chan ECY
Clin Pharmacol Ther; 2022 Oct; 112(4):803-807. PubMed ID: 35712802
[TBL] [Abstract][Full Text] [Related]
15. Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19).
Loza A; Farias R; Gavin N; Wagner R; Hammer E; Shields A
Obstet Gynecol; 2022 Sep; 140(3):447-449. PubMed ID: 36356238
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
Lingscheid T; Kinzig M; Krüger A; Müller N; Bölke G; Tober-Lau P; Münn F; Kriedemann H; Witzenrath M; Sander LE; Sörgel F; Kurth F
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0122922. PubMed ID: 36286542
[TBL] [Abstract][Full Text] [Related]
17. Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019.
Hiremath S; Blake PG; Yeung A; McGuinty M; Thomas D; Ip J; Brown PA; Pandes M; Burke A; Sohail QZ; To K; Blackwell L; Oliver M; Jain AK; Chagla Z; Cooper R
Clin J Am Soc Nephrol; 2023 Apr; 18(4):485-490. PubMed ID: 36723285
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S
Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS.
Qin F; Wang H; Li M; Zhuo S; Liu W
Expert Opin Drug Saf; 2023; 22(12):1321-1327. PubMed ID: 37477905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
